Why work with an incomplete toolbox when you can routinely apply single-cell genomics in cardiovascular disease research?
Cardiovascular diseases (CVDs)—including coronary (ischemic), congenital, hypertensive, and rheumatic heart disease, cardiomyopathy, arrhythmia, and other diseases of the heart and blood vessels—are common, and are the leading cause of death and disability worldwide.
Although associated with known behavioral, environmental, and socioeconomic risk factors, a substantial subset of CVDs is directly caused by gene mutations, or are modified by genetic variation. Multi-omics and single-cell analyses are becoming increasingly important in the elucidation of the genetic basis of CVD. Whilst single-cell transcriptomic and epigenomic methods are well established, the application of single-cell genomics in cardiology has been hampered by the limitations of whole-genome amplification (WGA) technologies.
BioSkryb’s robust and scalable WGA technology (PTA) and powerful bioinformatics platform (BaseJumper™) enables the integration of single-cell genomics in routine clinical and translational cardiology research. With PTA, it is possible to sequence individual cardiomyocytes to detect autonomous cell genetic defects/variation, and genetically profile endothelial cells and fibroblasts in the microenvironment potentially impacts cardiomyocytes. As such, it enables us to utilize the full toolbox of next-generation omics methodologies to support the evolution of personalized management practices for CVDs.